Report Package: Hot targets for empowered antibody and cell therapy technologies

Publisher: La Merie Publishing
Pages: 202
Format: PDF
Product Line:
Brief Report
Product Code: LMBR0015
Release Date: December of 2016

1,900.00 €
(Discount: 40.00%)
1,140.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Report Package: Hot targets for empowered antibody and cell therapy technologies

This package contains three reports analyzing

  • BCMA,
  • CD123 and
  • CD22

as versatile and hot targets for the successful application of empowered antibody and cell technologies, including:

  • Fc-Engineered Antibodies;
  • Radioimmunotherapy;  
  • Immunotoxins;
  • Antibody-Drug Conjugates;
  • T-Cell Redirecting Bispecific Antibodies;
  • Chimeric Antigen Receptor (CAR) T-Cells.

The reports describe and discuss

  • Target background, scientific rationale & expression profiles;
  • Preclinical proof-of-concept;
  • Clinical experience;
  • Competitive landscape;
  • Drug or cell therapy profiles;
  • Company profiles.

Each of the three reports can be obtained individually, but the package of the three reports provides a 40% discount on the regular prices:

B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

CD123: a paradigmatic target for immunotherapeutic treatment modalities

CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Detailed report descriptions, tables of contents and samples from the reports can be found on the respective product page.

Report Package: Hot targets for empowered antibody and cell therapy technologies

Tables of Content

Report 1:
B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Target Background
Target Antigen Expression Profile
Preclinical Proof-of-Concept
Clinical Indications & Treatment Options
Clinical Experience with BCMA-Targeted Treatment Modalities
Treatment Modalities & Competitive Landscape

  • Drug & Cell Therapy Candidate Profiles
  • CAR T-Cells
  • Antibody-Drug Conjugate (ADC)
  • T-Cell Redirecting Antibodies

Company Profiles
References

 

Report 2:
CD123: a paradigmatic target for immunotherapeutic treatment modalities

Target Background & Scientific Rationale
Preclinical Proof-of-Concept of Anti-CD123 Immunotherapeutics
Clinical Experience with CD123-Targeted Treatment Modalities
Target and Treatment Modality Safety Concerns of anti-CD123 Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD123 Immunotherapeutics:

  • Immunotoxins
  • Naked Antibody
  • Fc-Engineered Antibodies
  • Antibody-Drug Conjugates
  • T-Cell Redirecting Bispecific Antibodies
  • Anti-CD123 CAR T-Cells

Company Profiles
References
ADDENDUM: Competitor Analysis of CD123-Targeted Immunotherapeutics

 

Report 3:
CD22: a suitable antigen for targeted payload delivery by immunotherapeutics

Target Background & Scientific Rationale
Clinical Proof-of-Concept of CD22-Targeted Immunotherapeutics
Competitive Landscape
Profiles of Anti-CD22 Immunotherapeutics

  • Naked antibodies;
  • Radioimmunotherapy (RIT);
  • Immunotoxins (IT);
  • Antibody-Dug Conjugates (ADC); and
  • Chimeric Antigen Receptor (CAR) T-Cells.

Profiles of Companies with CD22-Targeted Immunotherapeutics
References
ADDENDUM: Competitor Analysis of of CD22-Targeted Immunotherapeutics



The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top